Literature DB >> 11393166

New concepts in characterization of ischemically injured myocardium by MRI.

M Saeed1.   

Abstract

New concepts regarding the assessment of ischemic myocardial injuries have been addressed in this Minireview using magnetic resonance imaging (MRI). MRI, with its different techniques, brings not only anatomic, but also physiologic, information on ischemic heart disease. It has the ability to measure identical parameters in preclinical and clinical studies. MRI techniques provide the ideal package for repeated and noninvasive assessment of myocardial anatomy, viability, perfusion, and function. MR contrast agents can be applied in a variety of ways to improve MRI sensitivity for detecting and assessing ischemically injured myocardium. With MR contrast agents protocol, it becomes possible to identify ischemic, acutely infarcted, and peri-infarcted myocardium in occlusive and reperfused infarctions. Necrosis specific and nonspecific extracellular contrast-enhanced MRI has been used to assess myocardial viability. Contrast-enhanced perfusion MRI can explore the disturbances in large (angiography) and small coronary arteries (myocardial perfusion) as the underlying cause of myocardial dysfunction. Perfusion MRI has been used to measure myocardial perfusion (ml/min/g) and to demonstrate the difference in transmural myocardial blood flow. Information on no-reflow phenomenon is derived from dynamic changes in regional signal intensity after bolus injection of MR contrast agents. Another development is the near future availability of blood pool MR contrast agents. These agents are able to assess microvascular permeability and integrity and are advantageous in MR angiography (MRA) due to their persistence in the blood. Noncontrast-enhanced MRI such as cine MRI at rest/stress, sodium MRI, and MR spectroscopy also have the potential to noninvasively assess myocardial viability in patients. Futuristic applications for MRI in the heart will focus on identifying coronary artery disease at an early stage and the beneficial effects of new therapeutic agents such as intra-arterial gene therapy. MR techniques will have great future in the drug discovery process and in testing the effects of drugs on myocardial biochemistry, physiology, and morphology. Molecular imaging is going to bloom in this decade.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11393166     DOI: 10.1177/153537020122600502

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  5 in total

Review 1.  Dynamic contrast-enhanced magnetic resonance imaging: fundamentals and application to the evaluation of the peripheral perfusion.

Authors:  Yaron Gordon; Sasan Partovi; Matthias Müller-Eschner; Erick Amarteifio; Tobias Bäuerle; Marc-André Weber; Hans-Ulrich Kauczor; Fabian Rengier
Journal:  Cardiovasc Diagn Ther       Date:  2014-04

Review 2.  A review of responsive MRI contrast agents: 2005-2014.

Authors:  Dina V Hingorani; Adam S Bernstein; Mark D Pagel
Journal:  Contrast Media Mol Imaging       Date:  2014-10-29       Impact factor: 3.161

3.  First-pass perfusion CMR two days after infarction predicts severity of functional impairment six weeks later in the rat heart.

Authors:  Daniel J Stuckey; Carolyn A Carr; Stephanie J Meader; Damian J Tyler; Mark A Cole; Kieran Clarke
Journal:  J Cardiovasc Magn Reson       Date:  2011-08-03       Impact factor: 5.364

4.  Bone marrow-derived stromal cells home to and remain in the infarcted rat heart but fail to improve function: an in vivo cine-MRI study.

Authors:  Carolyn A Carr; Daniel J Stuckey; Louise Tatton; Damian J Tyler; Sarah J M Hale; Dominic Sweeney; Jürgen E Schneider; Enca Martin-Rendon; George K Radda; Sian E Harding; Suzanne M Watt; Kieran Clarke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-06       Impact factor: 4.733

5.  Myocardial Viability Imaging using Manganese-Enhanced MRI in the First Hours after Myocardial Infarction.

Authors:  Nur Hayati Jasmin; May Zaw Thin; Robert D Johnson; Laurence H Jackson; Thomas A Roberts; Anna L David; Mark F Lythgoe; Philip C Yang; Sean M Davidson; Patrizia Camelliti; Daniel J Stuckey
Journal:  Adv Sci (Weinh)       Date:  2021-04-02       Impact factor: 17.521

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.